Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Improved RCC survival attributed to better therapy, not earlier diagnosis

Patel HD et al. Eur Urol Oncol. 2018 Sep 25. doi: 10.1016/j.euo.2018.08.023

Publish date:: October 4, 2018

Key clinical point: Improved renal cell carcinoma survival appears to be attributable to improvements in therapy rather than increased diagnosis of early-stage disease.

Major finding: 5-year survival increased from 9.8% in 2004 to 13.2% in 2010 for patients with distant metastatic disease.

Study details: Retrospective analysis of data from the National Cancer Database on 262,597 patients diagnosed with RCC from 2004 through 2015.

Disclosures: No study funding source was reported. Dr. Patel and coauthors reported having no conflicts of interest to disclose.

Read the article.

Citation:

Patel HD et al. Eur Urol Oncol. 2018 Sep 25. doi: 10.1016/j.euo.2018.08.023

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Renal Cell Carcinoma

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Fear of recurrence highly prevalent in RCC survivors,

Risk factors for severe immune-related AEs identified,

Pembrolizumab plus axitinib continues to outshine sunitinib for advanced RCC,